SGN-LIV1A for breast cancer: Is this new news? (It sounds new to me.)
From today's press release: In addition, preclinical data demonstrate activity of a new ADC for metastatic breast cancer, SGN-LIV1A, utilizing the same proprietary ADC technology as ADCETRIS® (brentuximab vedotin)....
SGN-LIV1A is an ADC that targets LIV-1, which is expressed in most subtypes of metastatic breast cancer. Preclinical data demonstrated that up to 92 percent of breast tumors analyzed expressed LIV-1, while expression was limited in normal tissue. SGN-LIV1A is comprised of an anti-LIV-1 monoclonal antibody linked to a synthetic cell-killing agent called monomethyl auristatin E (MMAE). SGN-LIV1A demonstrated significant antitumor activity in multiple preclinical models at well-tolerated doses. Seattle Genetics plans to submit an IND and initiate a phase 1clinical trial of SGN-LIV1A for breast cancer in 2013. (Abstract 3962)
First time that I'm hearing about it also.
Not surprised if it is new because this is an extremely well managed company and the RD monies are not bein sunken down just to keep the "old" stuff relevant. This company is very real and populated with very smart scientists and innovators and that is one big reason for a significant and growing part of my retirement funds to be parked here.